title: Control of drooling using transdermal scopolamine skin patches. A case report.
abstract: Transdermal scopolamine has been shown to be very useful in the management of drooling, particularly in patients with neurological or neuropsychiatric disturbances or severe developmental disorders. In this paper, we present the case of a 24-year-old patient with a diagnosis of cerebral palsy and a severe problem of drooling, exacerbated by marked mandibular prognathism. After exclusion of other therapeutic alternatives, it was decided to use sustained-release transdermal scopolamine patches (Scopoderm TTS). This technique consists of the application every three days of a patch with 1.5 mg of scopolamine in the area of the mastoid apophysis; the patch releases a dose of 0.5 mg of the active substance over each 24 hour period. The patient underwent periodic clinical and laboratory follow-up over a period of three years, achieving satisfactory results with no significant undesirable effects.
authors.affiliation: Departamento de Estomatología, Unidad de Pacientes Especiales, Facultad de Medicina y Odontología, Universidad de Santiago de Compostela, Spain.
authors.forename: Abigail
authors.initials: A
authors.lastname: Mato Montero
authors.forename: Jacobo
authors.initials: J
authors.lastname: Limeres Posse
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Tomás Carmona
authors.forename: Javier
authors.initials: J
authors.lastname: Fernández Feijoo
authors.forename: Pedro
authors.initials: P
authors.lastname: Diz Dios
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D002547:Cerebral Palsy / Q000150:complications*; D006801:Humans; D008607:Intellectual Disability / Q000150:complications; D008297:Male; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D011378:Prognathism / Q000150:complications; D012601:Scopolamine / Q000008:administration & dosage*; D012798:Sialorrhea / Q000188:drug therapy* / Q000209:etiology
chemical_list: D018727:Muscarinic Antagonists; D012601:Scopolamine